Annual report 2021
To reflect the broad aspects of Novo Nordisk across therapy areas and geographies, Novo Nordisk introduced in 2019 a comprehensive approach describing the future growth aspirations of the company under the headline Strategic Aspirations 2025.
The strategic aspirations are objectives that Novo Nordisk intends to work towards and are not a projection of Novo Nordisk's financial outlook or expected growth.
2025 strategic aspirations
2021 highlights
Adding value to society:
Progress towards zero environmental impact:
2025 strategic aspirations
2021 highlights
Further raise innovation bar for diabetes treatment:
Strengthen and progress Biopharm pipeline:
Establish presence in other serious chronic diseases:
Acquisition of Dicerna Pharmaceuticals and its RNAi platformto be applied across therapy areas
2025 strategic aspirations
2021 highlights
Strengthen diabetes leadership to more than one-third:
Strengthen obesity leadership and double sales:
Secure a sustained growth outlook for Biopharm:
2025 strategic aspirations
Drive operational efficiencies:
Enable attractive capital allocation to shareholders:
Read the full story in the report
140,800
DKK million in net sales
58,644
DKK million in operating profit
48,478
DKK million in net profit
28,565
DKK million in free cash flow